Description
Lamivudine is an antiviral compound clinically used as a treatment for hepatitis B infection; it acts as a thymidine analog, inhibiting the reverse transcriptase enzyme. In two separate in vitro models, lamivudine decreased HIV production in recently infected resting cells and inhibited growth of HIV-infected cells at low concentrations. Additionally, lamivudine increases insulin resistance when given with zidovudine in clinical settings.
References
Blümer RM, van Vonderen MG, Sutinen J, et al. Zidovudine/lamivudine contributes to insulin resistance within 3 months of starting combination antiretroviral therapy. AIDS. 2008 Jan 11;22(2):227-36. PMID: 18097225.
Saavedra-Lozano J, McCoig CC, Cao Y, et al. Zidovudine, lamivudine, and abacavir have different effects on resting cells infected with human immunodeficiency virus in vitro. Antimicrob Agents Chemother. 2004 Aug;48(8):2825-30. PMID: 15273087
Balestrieri E, Forte G, Matteucci C, et al. Effect of lamivudine on transmission of human T-cell lymphotropic virus type 1 to adult peripheral blood mononuclear cells in vitro. Antimicrob Agents Chemother. 2002 Sep;46(9):3080-3. PMID: 12183277.